Gerry Wilson


Gerry Wilson

Professor of Rheumatology

Professor Gerry Wilson graduated in Medicine from Queen’s University Belfast in 1983.  He was awarded an ARC Clinical Fellowship for a PhD thesis, which he undertook at the University of Sheffield and completed in 1995.  He was subsequently awarded an ARC Copeman research fellowship at Stanford University.  He was appointed Professor of Rheumatology and Honorary Consultant Rheumatologist at Sheffield University Medical School and Sheffield Teaching Hospitals NHS Foundation Trust, where he was Head of the Sheffield EULAR Centre of Excellence for Rheumatology.

Prof. Wilson was appointed to the Arthritis Ireland/UCD Chair of Rheumatology in 2013. He joins Ireland’s leading rheumatology group, comprising seven existing consultant rheumatologists based Mater Misericordiae University Hospital and St Vincent’s University Hospital. Prof Wilson is the head of the UCD Centre for Arthritis Research.

Gerry Wilson

Professor of Rheumatology

Niamh Morgan
Position: Post-doctoral Scientist
niamh.morgan@ucd.ie

Role:
Post-doctoral scientist

Down Syndrome-related Arthritis

Down syndrome is a chromosomal disorder caused by full Trisomy 21 (95%), Robertsonian Translocation or Mosaicism. Approximately 110 babies with Down syndrome are born in Ireland each year, making Ireland’s birth rate of children with Down syndrome the highest in Europe. This puts Irish researchers in a unique position to engage in robust research into conditions that affect children with Down syndrome. A variety of medical conditions and immunological abnormalities are associated with Down syndrome. Immune dysregulation predisposes children with Down syndrome to high frequencies of haematologic malignancies, increased susceptibility to infections, and, most remarkably, a high incidence of autoimmune diseases, including arthritis. DA is an inflammatory joint condition affecting children with Down syndrome. The NCPR at OLCHC provides care to 40 children with DA, the largest reported cohort worldwide. Our research has demonstrated that the prevalence of DA is 18-21 times greater than Juvenile Idiopathic Arthritis (JIA) (JIA prevalence 1/1000).

An investigation of the mechanisms linking C5orf30 with tissue damage in Rheumatoid Arthritis

Does genetic correlation mean disease causation? Arthritis is the single biggest cause of disability in Ireland. We carry out studies comparing the frequency of genetic variations in people with rheumatic disease versus healthy individuals. Results showed that a number of these genetic variations were present more often in individuals with disease, suggesting they may be associated with increased risk of developing the disease. Often, novel (new or previously unknown) variants are overlooked due to a lack of information or inability to use standard techniques to study them. My research focuses on studying these novel genes and variants to determine if there is a biological rationale for causation of disease rather than mere correlation with disease. The novel gene I’m currently investigating is called C5orf30. A variant within C5orf30 is associated with both risk and severity of rheumatoid arthritis (RA). To date, our research has demonstrated that C5orf30 does indeed have a causative role and is a previously unknown regulator of both tissue damage in RA and resolution of inflammation by immune cells.

Self Management of Rheumatoid Arthritis

How do people experience the burden of self-managing a chronic illness? It is a burden that is largely invisible and often difficult to express to family, friends and health care professionals. My project involves working with patients of rheumatoid arthritis to capture their “lived experience” and facilitate a better understanding of everyday life with a chronic illness. It will rely on participation and collaboration between the researcher and the researched. Ultimately, this work intends to improve society’s understanding of what it is like for people to self-manage rheumatoid arthritis and devise ways to best support them.

Genetics of Rare Diseases

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory disease of childhood which affects ten child per million. Auto-inflammatory diseases lead to recurrent episodes of inflammation in specific parts of the body with no obvious trigger. This study will look at a large Irish CRMO population using state-of-the-art technology to study patients’ genes. Genes are made of parts called introns and exons. Exons are the part of the gene that make proteins. Proteins tell a cell what type of cell it is and how it should behave. All the exons together are called the exome. The specific genetic test we propose to do is called whole exome sequencing and looks at the whole exome. Scientists compare the sequence of a patient’s exome with that of a normal exome. The location of differences in the sequence are marked. If the difference affects genes that control bone growth, inflammation and the immune system it will be studied further because it may cause CRMO.

Development of a Rheumatoid Arthritis Prognostic Score

Rheumatoid Arthritis (RA) varies from a mild to a severe, unremitting illness characterized by uncontrolled inflammation with consequent damage to cartilage and bone of joints. It is now known that our DNA determines the likelihood of severity of disease. The study of patients DNA can then facilitate personalized approach where patients likely to develop severe disease will receive more aggressive treatment compared to the patients with mild disease. My project will identify genetic variants associated with severity of RA which will help us to establish a risk prediction score for early identification and stratification of patients. The results obtained during this study will also assist the clinicians in determining the optimal treatment to be given to patients, more quickly and efficiently.

The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

Nair N, Wilson AG, 2019 Oct 10, Can machine learning predict responses to TNF inhibitors? Nat Rev Rheumatol, DOI: 10.1038/s41584-019-0320-9
Nair N, Plant D, Verstappen SM, Isaacs JD, Morgan AW, Hyrich KL, Barton A, Wilson AG, 2019 Oct 10, Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kez411
Wilson AG, Sherwin J, Dorris ER, 2019 Nov, Patient and public involvement in biomedical research: training is not a substitute for relationship building. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2019-215595
Maccarthy J, Guerin S, Wilson AG, Dorris ER, 2019, Facilitating public and patient involvement in basic and preclinical health research. PLoS One, DOI: 10.1371/journal.pone.0216600
Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P, 2019 Aug, Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2018-214877
Dorris ER, Tazzyman SJ, Moylett J, Ramamoorthi N, Hackney J, Townsend M, Muthana M, Lewis MJ, Pitzalis C, Wilson AG, 2019 Feb 15, The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. J Immunol, DOI: 10.4049/jimmunol.1801155
Massey J, Plant D, Hyrich K, Morgan AW, Wilson AG, Spiliopoulou A, Colombo M, McKeigue P, Isaacs J, Cordell H, Pitzalis C, Barton A, BRAGGSS, MATURA Consortium., 2018 Sep, Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics J, DOI: 10.1038/s41397-018-0040-6
Daghestani HN, Jordan JM, Renner JB, Doherty M, Wilson AG, Kraus VB, 2017, Serum N-propeptide of collagen IIA (PIIANP) as a marker of radiographic osteoarthritis burden. PLoS One, DOI: 10.1371/journal.pone.0190251
Savic S, Mistry A, Wilson AG, Barcenas-Morales G, Doffinger R, Emery P, McGonagle D, 2017, Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases. RMD Open, DOI: 10.1136/rmdopen-2017-000550
Nair N, Wilson AG, Barton A, 2017 Sep, DNA methylation as a marker of response in rheumatoid arthritis. Pharmacogenomics, DOI: 10.2217/pgs-2016-0195
Chaudhry M, Wilson AG, 2017 Sep, The role of genetic analysis for predicting outcome of rheumatoid arthritis. Expert Rev Mol Diagn, DOI: 10.1080/14737159.2017.1355732
Smith SL, Plant D, Eyre S, Hyrich K, Morgan AW, Wilson AG, Isaacs JD, Barton A, 2017 Jun 1, The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kew387
Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA, ACCORD/ACCORDion Investigators., 2016, Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. Front Genet, DOI: 10.3389/fgene.2016.00138
Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, 2016 Nov, Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kew299
Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, BRAGGSS., 2017 Jan, High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2015-208849
Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Barton A, 2016 May, Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics, DOI: 10.2217/pgs.16.16
Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, Hyrich KL, Wilson AG, Morgan AW, Isaacs JD, Worthington J, Barton A, 2016 Jun, Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, DOI: 10.1002/art.39590
Smith SL, Eyre S, Yarwood A, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate 6., Plant D, Barton A, 2015 Dec 14, Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Res Ther, DOI: 10.1186/s13075-015-0868-y
Hsu YH, Liu Y, Hannan MT, Maixner W, Smith SB, Diatchenko L, Golightly YM, Menz HB, Kraus VB, Doherty M, Wilson AG, Jordan JM, 2015 Nov, Genome-wide association meta-analyses to identify common genetic variants associated with hallux valgus in Caucasian and African Americans. J Med Genet, DOI: 10.1136/jmedgenet-2015-103142
Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U, Veale D, Ciani B, Wilson AG, 2015 Sep 15, C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proc Natl Acad Sci U S A, DOI: 10.1073/pnas.1501947112
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Morgan AW, Wilson AG, Hyrich KL, Isaacs J, Barton A, 2015 Feb 26, Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet, DOI: 10.1016/S0140-6736(15)60363-4
Wilson AG, Chan Y, Taylor SS, Arcese P, 2015, Genetic Divergence of an Avian Endemic on the Californian Channel Islands. PLoS One, DOI: 10.1371/journal.pone.0134471
Hawtree S, Muthana M, Wilkinson JM, Akil M, Wilson AG, 2015 Oct 1, Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. Hum Mol Genet, DOI: 10.1093/hmg/ddv258
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators., 2015 May, Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol, DOI: 10.1002/art.39169
Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, Symmons DP, Worthington J, Young A, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Raychaudhuri S, Barton A, 2015 Apr 28, Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA, DOI: 10.1001/jama.2015.3435
Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez Mdel C, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Gómez-Reino JJ, Gonzalez A, 2015 Mar 18, Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. Arthritis Res Ther, DOI: 10.1186/s13075-015-0571-z
Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Cordingley L, Barton A, BRAGGSS., 2015 Mar, Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford), DOI: 10.1093/rheumatology/keu358
Knevel R, de Rooy DP, Saxne T, Lindqvist E, Leijsma MK, Daha NA, Koeleman BP, Tsonaka R, Houwing-Duistermaat JJ, Schonkeren JJ, Toes RE, Huizinga TW, Brouwer E, Wilson AG, van der Helm-van Mil AH, 2014 May 7, A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res Ther, DOI: 10.1186/ar4558
Plant D, Wilson AG, Barton A, 2014 Jun, Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol, DOI: 10.1038/nrrheum.2014.16
Orozco G, Viatte S, Bowes J, Martin P, Wilson AG, Morgan AW, Steer S, Wordsworth P, Hocking LJ, UK Rheumatoid Arthritis Genetics Consortium., Wellcome Trust Case Control Consortium., Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Consortium., Barton A, Worthington J, Eyre S, 2014 Jan, Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. Arthritis Rheumatol, DOI: 10.1002/art.38196
Cordingley L, Prajapati R, Plant D, Maskell D, Morgan C, Ali FR, Morgan AW, Wilson AG, Isaacs JD, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Barton A, 2014 Jun, Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken), DOI: 10.1002/acr.22249
Yarwood A, Viatte S, Plant D, Morgan AW, Isaacs J, Wilson AG, Hyrich K, Eyre S, Barton A, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., 2014 May, Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2013-204443
Scott IC, Seegobin SD, Steer S, Tan R, Forabosco P, Hinks A, Eyre S, Morgan AW, Wilson AG, Hocking LJ, Wordsworth P, Barton A, Worthington J, Cope AP, Lewis CM, 2013, Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet, DOI: 10.1371/journal.pgen.1003808
Gay S, Wilson AG, 2014 Mar, The emerging role of epigenetics in rheumatic diseases. Rheumatology (Oxford), DOI: 10.1093/rheumatology/ket292
McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ, Steer S, Wordsworth P, Wilson AG, Morgan AW, UK Rheumatoid Arthritis Genetics Consortium., Rheumatoid Arthritis Consortium International., Kremer JM, Pappas D, Gregersen P, Klareskog L, Plenge R, Barton A, Greenberg J, Worthington J, Eyre S, 2013 Dec, Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. Arthritis Rheum, DOI: 10.1002/art.38183
Krabben A, Wilson AG, de Rooy DP, Zhernakova A, Brouwer E, Lindqvist E, Saxne T, Stoeken G, van Nies JA, Knevel R, Huizinga TW, Toes R, Gregersen PK, van der Helm-van Mil AH, 2013 Dec, Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. Arthritis Rheum, DOI: 10.1002/art.38141
Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, BRAGGSS., Barton A, 2014 Apr, Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics J, DOI: 10.1038/tpj.2013.26
Teare MD, Knevel R, Morgan MD, Kleszcz A, Emery P, Moore DJ, Conaghan P, Huizinga TW, Morgan AW, van der Helm-van Mil AH, Wilson AG, 2013 Oct, Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. Arthritis Rheum, DOI: 10.1002/art.38064
Bickel WK, Koffarnus MN, Moody L, Wilson AG, 2014 Jan, The behavioral- and neuro-economic process of temporal discounting: A candidate behavioral marker of addiction. Neuropharmacology, DOI: 10.1016/j.neuropharm.2013.06.013
Hawtree S, Muthana M, Wilson AG, 2013 Jun, The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Biochem Soc Trans, DOI: 10.1042/BST20130053
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF, 2014 Jun, Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2013-203276
Taylor LH, Twigg S, Worthington J, Emery P, Morgan AW, Wilson AG, Teare MD, 2013 Jul, Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis. J Rheumatol, DOI: 10.3899/jrheum.120784
Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM, 2013 Mar, Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet, DOI: 10.1371/journal.pgen.1003394
Knevel R, Krabben A, Wilson AG, Brouwer E, Leijsma MK, Lindqvist E, de Rooy DP, Daha NA, van der Linden MP, Tsonaka S, Zhernakova A, Westra HJ, Franke L, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Saxne T, van der Helm-van Mil AH, 2013 Mar, A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum, DOI: 10.1002/art.37808
Zaitlen N, Lindström S, Pasaniuc B, Cornelis M, Genovese G, Pollack S, Barton A, Bickeböller H, Bowden DW, Eyre S, Freedman BI, Friedman DJ, Field JK, Groop L, Haugen A, Heinrich J, Henderson BE, Hicks PJ, Hocking LJ, Kolonel LN, Landi MT, Langefeld CD, Le Marchand L, Meister M, Morgan AW, Raji OY, Risch A, Rosenberger A, Scherf D, Steer S, Walshaw M, Waters KM, Wilson AG, Wordsworth P, Zienolddiny S, Tchetgen ET, Haiman C, Hunter DJ, Plenge RM, Worthington J, Christiani DC, Schaumberg DA, Chasman DI, Altshuler D, Voight B, Kraft P, Patterson N, Price AL, 2012, Informed conditioning on clinical covariates increases power in case-control association studies. PLoS Genet, DOI: 10.1371/journal.pgen.1003032
de Rooy DP, Yeremenko NG, Wilson AG, Knevel R, Lindqvist E, Saxne T, Krabben A, Leijsma MK, Daha NA, Tsonaka S, Zhernakova A, Houwing-Duistermaat JJ, Huizinga TW, Toes RE, Baeten DL, Brouwer E, van der Helm-van Mil AH, 2013 May, Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2012-202184
Plant D, Ibrahim I, Lunt M, Eyre S, Flynn E, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, BRAGGGSS., Barton A, 2012 Oct 7, Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther, DOI: 10.1186/ar4052
Maxwell JR, Marinou I, Kuet KP, Orozco G, Moore DJ, Barton A, Worthington J, Wilson AG, 2012 Sep, Rheumatoid arthritis-associated polymorphisms at 6q23 are associated with radiological damage in autoantibody-positive RA. J Rheumatol, DOI: 10.3899/jrheum.120144
Maxwell JR, Gowers IR, Kuet KP, Barton A, Worthington J, Wilson AG, 2012 Aug, Expression of the autoimmunity associated TNFAIP3 is increased in rheumatoid arthritis but does not differ according to genotype at 6q23. Rheumatology (Oxford), DOI: 10.1093/rheumatology/kes134
Knevel R, de Rooy DP, Gregersen PK, Lindqvist E, Wilson AG, Gröndal G, Zhernakova A, van Nies JA, Toes RE, Tsonaka R, Houwing-Duistermaat JJ, Steinsson K, Huizinga TW, Saxne T, van der Helm-van Mil AH, 2012 Oct, Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2012-201289
Mackie SL, Taylor JC, Twigg S, Martin SG, Steer S, Worthington J, Barton A, Wilson AG, Hocking L, Young A, Emery P, Barrett JH, Morgan AW, 2012 Oct, Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2011-201003
Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E, Saxne T, de Rooy D, Daha N, van der Linden MP, Stoeken G, van Toorn L, Koeleman B, Tsonaka R, Zhernakoza A, Houwing-Duistermaat JJ, Toes R, Huizinga TW, van der Helm-van Mil A, 2012 Oct, Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis, DOI: 10.1136/annrheumdis-2011-200724
IL6R Genetics Consortium Emerging Risk Factors Collaboration., Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjærg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundström J, Wassertheil-Smoller S, Mellström D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten Å, Ljunggren Ö, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Hólm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J, 2012 Mar 31, Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet, DOI: 10.1016/S0140-6736(11)61931-4
Robinson JI, Carr IM, Cooper DL, Rashid LH, Martin SG, Emery P, Isaacs JD, Barton A, BRAGGSS., Wilson AG, Barrett JH, Morgan AW, 2012 Apr, Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. Hum Mutat, DOI: 10.1002/humu.22031
Gowers IR, Walters K, Kiss-Toth E, Read RC, Duff GW, Wilson AG, 2011 Dec, Age-related loss of CpG methylation in the tumour necrosis factor promoter. Cytokine, DOI: 10.1016/j.cyto.2011.09.009
Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate., Barton A, 2012 Mar, Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum, DOI: 10.1002/art.33381
Mackie SL, Taylor JC, Martin SG, YEAR Consortium., UKRAG Consortium., Wordsworth P, Steer S, Wilson AG, Worthington J, Emery P, Barrett JH, Morgan AW, 2012 Feb, A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. Genes Immun, DOI: 10.1038/gene.2011.60
Orozco G, Eyre S, Hinks A, Bowes J, Morgan AW, Wilson AG, Wordsworth P, Steer S, Hocking L, UKRAG consortium., Thomson W, Worthington J, Barton A, 2011 Mar, Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis, DOI: 10.1136/ard.2010.137174
Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Wellcome Trust Case Control Consortium., British Society for Rheumatology Biologics Register., Barton A, 2011 Mar, Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum, DOI: 10.1002/art.30130

Please visit PubMed for more information on Gerry Wilson's publications

Funding Agency:National Children's Research Centre
Project Title:Characterisation of the pathogenic basis of an early-onset familial mucocutaneous ulcerative condition.
Start Date/End Date:1st October 2018 (3 years)
Total Awarded:€265,079
Role:Principal Investigator
Funding Agency:Health Research Board/Arthritis Ireland
Project Title:An investigation of the mechanisms linking C5orf30 with tissue damage in RA.
Start Date/End Date:1st April 2017 (3 years)
Total Awarded:€256,540
Role:Principal Investigator
Name:Prof. Cormac Taylor
Position:Professor in School of Medicine
Email:cormac.taylor@ucd.ie
Role:Co-Principal Investigator
Department School of Medicine
Institution:University College Dublin
Country:Ireland
Name:Dr. Eoin Cummins
Position:Assistant Professor in Physiology
Email:eoin.cummins@ucd.ie
Role:Co-Principal Investigator
DepartmentSchool of Medicine
Institution:University College Dublin
Country:Ireland